At present, PARP inhibitors targeting breast cancer susceptibility gene (BRCA) mutations and trophoblast cell-surface antigen 2 (trop2) ADC drug sacituzumab govitecan (SG) have been used in clinical practice. Here, TACSTD2 is linked to cancer.